Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin

The vascular disrupting agent crolibulin binds to the colchicine binding site and produces anti-vascular and apoptotic effects. In a multisite phase 1 clinical study of crolibulin (NCT00423410), we measured treatment-induced changes in tumor perfusion and water diffusivity (ADC) using dynamic contra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorza, Andres M. Arias, Ravi, Harshan, Philip, Rohit C., Galons, Jean-Philippe, Trouard, Theodore P., Parra, Nestor A., Von Hoff, Daniel D., Read, William L., Tibes, Raoul, Korn, Ronald L., Raghunand, Natarajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468301/
https://www.ncbi.nlm.nih.gov/pubmed/32879326
http://dx.doi.org/10.1038/s41598-020-71246-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468301/
https://www.ncbi.nlm.nih.gov/pubmed/32879326
http://dx.doi.org/10.1038/s41598-020-71246-w

Ejemplares similares